2-oxindole compounds

Patent metadata

Field	Value
Publication number	US-10759789-B2
Application number	US-201916524618-A
Country	US
Kind code	B2
Filing date	Jul 29, 2019
Priority date	Jan 20, 2016
Publication date	Sep 1, 2020
Grant date	Sep 1, 2020

Abstract

Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.

First claim

What is claimed is:

1. A method of treating a CCR(9) mediated disease or condition in a subject in need thereof, said method comprising administering to said subject an effective amount of a compound having formula (I)

or a pharmaceutically acceptable salt thereof, wherein
Ar is a 5- to 10-membered aromatic or heteroaromatic ring, optionally substituted with from one to three R 3 ;
L 1 is selected from the group consisting of a bond, C 1-6 alkylene, and C 1-6 heteroalkylene,
L 2 is selected from the group consisting of a bond, C 1-6 alkylene, and C 1-6 heteroalkylene,
Y is CO 2 H or a carboxylic acid bioisostere;
each R 1 and each R 2a is independently selected from the group consisting of halogen, cyano, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 3-6 cycloalkyl, and C 2-6 alkenyl, wherein the alkyl, cycloalkyl and alkenyl portions are optionally substituted with from one to three members selected from fluoro, OH, CN, C 1-3 alkyl, C 1-3 haloalkyl, and C 1-3 alkoxy;
R 2b is selected from the group consisting of H, halogen, cyano, C 1-6 alkyl, C 1-6 alkoxy, C 3-6 cycloalkyl, and C 2-6 alkenyl, wherein the alkyl, cycloalkyl and alkenyl portions are optionally substituted with from one to three members selected from fluoro, CN, C 1-3 alkyl, C 1-3 haloalkyl, and C 1-3 alkoxy;
or optionally one R 2a and R 2b when on adjacent vertices of a phenyl ring, may be joined together to form a 5- or 6-membered heterocycloalkyl ring having one or two ring vertices independently selected from O, N and S, wherein said heterocycloalkyl ring is optionally substituted with from one to three members selected from fluoro and C 1-3 alkyl;

each R 3 is independently selected from the group consisting of halogen, cyano, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 3-6 cycloalkyl, and C 2-6 alkenyl;
the subscript m is an integer of from 0 to 4; and
the subscript n is an integer of from 0 to 3
or a pharmaceutically acceptable salt thereof.

2. A method in accordance with claim 1 , wherein said disease or condition is selected from the group consisting of inflammatory bowel diseases, an allergic disease, psoriasis, atopic dermatitis, asthma, fibrotic diseases, graft rejection, immune mediated food allergies, autoimmune diseases, Celiac disease, rheumatoid arthritis, thymoma, thymic carcinoma, leukemia, Sjogren syndrome, GvHD (graft versus host disease), solid tumor, or acute lymphocytic leukemia, melanoma, primary sclerosing cholangitis, hepatitis and inflammatory hepatic disease or post-operative ileus.

3. A method in accordance with claim 1 , wherein said disease or condition is an inflammatory bowel diseases.

4. A method in accordance with claim 1 , wherein said disease or condition is selected from the group consisting of Crohn's disease and ulcerative colitis.

5. A method of claim 1 , wherein the compound has the formula

or a pharmaceutically acceptable salt thereof.

6. A method of claim 1 , wherein the compound has the formula

or a pharmaceutically acceptable salt thereof.

7. A method of claim 1 , wherein the compound has the formula

or a pharmaceutically acceptable salt thereof.

8. A method of claim 1 , wherein the compound has the formula

or a pharmaceutically acceptable salt thereof.

9. The method of claim 1 , wherein the compound has the formula (I′):

or a pharmaceutically acceptable salt thereof, wherein
Ar is a 5- to 10-membered aromatic or heteroaromatic ring, optionally substituted with from one to three R 3 ;
L 1 is selected from the group consisting of a bond, C 1-6 alkylene, and C 1-6 heteroalkylene,
L 2 is selected from the group consisting of a bond, C 1-6 alkylene, and C 1-6 heteroalkylene,
each R 1 and each R 2a is independently selected from the group consisting of halogen, cyano, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 3-6 cycloalkyl, and C 2-6 alkenyl, wherein the alkyl, cycloalkyl and alkenyl portions are optionally substituted with from one to three members selected from fluoro, CN, C 1-3 alkyl, C 1-3 haloalkyl, and C 1-3 alkoxy;
R 2b is selected from the group consisting of H, halogen, cyano, C 1-6 alkyl, C 1-6 alkoxy, C 3-6 cycloalkyl, and C 2-6 alkenyl, wherein the alkyl, cycloalkyl and alkenyl portions are optionally substituted with from one to three members selected from fluoro, CN, C 1-3 alkyl, C 1-3 haloalkyl, and C 1-3 alkoxy;
or optionally one R 2a and R 2b when on adjacent vertices of a phenyl ring, may be joined together to form a 5- or 6-membered heterocycloalkyl ring having one or two ring vertices independently selected from O, N and S, wherein said heterocycloalkyl ring is optionally substituted with from one to three members selected from fluoro and C 1-3 alkyl;

each R 3 is independently selected from the group consisting of halogen, cyano, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 3-6 cycloalkyl, and C 2-6 alkenyl;
the subscript m is an integer of from 0 to 4; and
the subscript n is an integer of from 0 to 3.

10. A method of claim 1 , wherein Y is selected from the group consisting of:

tetrazolyl and tetrazolonyl, wherein the tetrazolyl or tetrazolonyl is optionally substituted with R, wherein p is 0, 1 or 2 and wherein each R group is independently selected from the group consisting of H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 alkoxy, or C 1 -C 4 alkyl-O—C 1 -C 4 alkyl.

11. A method of claim 1 , wherein Y is selected from the group consisting of: tetrazolyl and tetrazolonyl, wherein the tetrazolyl or tetrazolonyl is optionally substituted with C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, —C 1-6 alkoxy or C 1-4 alkyl-O—C 1-4 alkyl.

12. A method of claim 1 , wherein the compound has the formula selected from the group consisting of:

or a pharmaceutically acceptable salt thereof, wherein said compound is substantially free of other isomers.

13. A method of claim 1 , wherein the compound has the formula:

or a pharmaceutically acceptable salt thereof, wherein L 2 is C 1-3 alkylene and wherein said compound is substantially free of other isomers.

14. A method of claim 1 , wherein Ar is selected from benzene, pyridine and quinoline, each of which is optionally substituted with from one to two R 3 .

15. A method of claim 1 , wherein L 1 is selected from the group consisting of a bond, —CH 2 — and —CH(CH 3 )—.

16. A method of claim 1 , wherein

Assignees

• Chemocentryx Inc

Inventors

• Chen Xi
• Dragoli Dean R
• Fan Pingchen
• Leleti Manmohan Reddy
• Lui Rebecca M
• Malathong Viengkham
• Powers Jay P
• Singh Rajinder
• Tanaka Hiroko
• Yang Ju
• Yu Chao
• Zhang Penglie

Classifications

• A61K31/404 Primary

  Indoles, e.g. pindolol · CPC title

• C07D405/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• C07D401/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• C07D209/34 Primary

  in position 2 · CPC title

• A61P19/00

  Drugs for skeletal disorders · CPC title